IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10092642 B1

PDFFull Text
Date of Patent:
Oct. 09, 2018

Filed:

Oct. 02, 2014

Mucosal vaccine composition

Applicant:

Nitto Denko Corporation, Osaka, JP;

Inventors:

Masahiro Fukasaka, Osaka, JP;

Mitsuhiko Hori, Osaka, JP;

Katsuyuki Okubo, Osaka, JP;

Daisuke Asari, Osaka, JP;

Arimichi Okazaki, Osaka, JP;

Eiji Kiyotoh, Osaka, JP;

Kyohei Matsushita, Osaka, JP;

Assignee:

NITTO DENKO CORPORATION, Osaka, JP;

Attorney:

Greenblum & Bernstein, P.L.C.

Primary Examiner:

Brian Gangle

Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/385 (2006.01); A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 39/04 (2006.01); A61K 39/09 (2006.01); A61K 39/08 (2006.01); A61K 39/13 (2006.01); A61K 39/145 (2006.01); A61K 39/15 (2006.01); A61K 39/155 (2006.01); A61K 39/165 (2006.01); A61K 39/20 (2006.01); A61K 39/205 (2006.01); A61K 39/25 (2006.01); A61K 39/29 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/385 (2013.01); A61K 9/006 (2013.01); A61K 39/04 (2013.01); A61K 39/08 (2013.01); A61K 39/092 (2013.01); A61K 39/12 (2013.01); A61K 39/13 (2013.01); A61K 39/145 (2013.01); A61K 39/15 (2013.01); A61K 39/155 (2013.01); A61K 39/165 (2013.01); A61K 39/20 (2013.01); A61K 39/205 (2013.01); A61K 39/25 (2013.01); A61K 39/29 (2013.01); A61K 39/292 (2013.01); C12N 7/00 (2013.01); A61K 2039/541 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/575 (2013.01); C12N 2710/16734 (2013.01); C12N 2710/20034 (2013.01); C12N 2720/12334 (2013.01); C12N 2730/10134 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18734 (2013.01); C12N 2760/20134 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/32434 (2013.01); C12N 2770/32634 (2013.01); C12N 2770/36234 (2013.01);
Abstract

The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of, and, or a salt thereof.

Find Patent Forward Citations

Loading…